Comparison of imatinib uptake by CEM and VBL100 cells in the presence or absence of ABCB1 inhibitors
. | Cell line . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Drug . | CEM* . | . | VBL100† . | . | |||
| Imatinib control | 123.1 (22.2) | P < .05 | 78.3 (18.4) | N/S | |||
| Imatinib + verapamil | 56.9 (7.4) | 56.3 (9.1) | |||||
| Imatinib control | 247.3 (42.0) | N/S | 95.5 (23.2) | P < .001 | |||
| Imatinib + PSC-833 | 239.7 (44.1) | - | 301.7 (35.8) | - | |||
. | Cell line . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| Drug . | CEM* . | . | VBL100† . | . | |||
| Imatinib control | 123.1 (22.2) | P < .05 | 78.3 (18.4) | N/S | |||
| Imatinib + verapamil | 56.9 (7.4) | 56.3 (9.1) | |||||
| Imatinib control | 247.3 (42.0) | N/S | 95.5 (23.2) | P < .001 | |||
| Imatinib + PSC-833 | 239.7 (44.1) | - | 301.7 (35.8) | - | |||
Data are presented as mean (SEM) of 4 observations.
In the CEM cell line, P < .05 when imatinib alone was compared with imatinib plus verapamil; the P value was not significant when imatinib alone was compared with imatinib plus PSC-833
In the VBL 100 cell line, the P value was not significant when imatinib alone was compared with imatinib plus verapamil; P < .001 when imatinib alone was compared with imatinib plus PSC-833